Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Exelixis Says FDA Approves Cabometyx in Combination With Opdivo

Jan. 22, 2021, 6:16 PM

Exelixis, Inc. received FDA approval of CABOMETYX for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with OPDIVO.

  • Approval is based on results from CheckMate -9ER trial
  • Exelixis shares currently up about 2.4%

To view the source of this information click here

To contact the reporter on this story:
Cara Moffat in Los Angeles at cmoffat@bloomberg.net

To contact the editor responsible for this story:
Lauren Berry at lberry4@bloomberg.net

© 2021 Bloomberg L.P. All rights reserved. Used with permission.